The data management scope-of-work arrives at a site coordinator’s desk in a PDF, forty-three pages, and somewhere around page twelve there is a section titled “Biometric Data Collection and Transfer.” It lists three eClinical platforms, two of which the site has never used, and a data dictionary that references CDISC SDTM standards the site’s EDC vendor has not yet implemented for the therapeutic area. The SIV is in six weeks. The site’s data manager retired in March. This is not a hypothetical — it is the pattern that shows up consistently when a sponsor has layered new digital biomarker requirements on top of an existing biometrics infrastructure that was designed for a different era of trials entirely.
The launch of Acrosian, the AI-focused biometrics CRO formed by the reunited founders of Quartesian, is worth reading carefully if you are making eClinical vendor decisions right now. Quartesian, founded in January 2003, built a strong reputation in clinical data management, biostatistics, statistical programming, and pharmacovigilance. The founders know legacy biometrics infrastructure from the inside. When that same team decides to rebuild from scratch for the AI era rather than upgrade what exists, that is a signal, not just a product launch.
Why Legacy Infrastructure Cracks Under AI-Era Demands
The honest diagnosis for most site operations teams is this: the eClinical stack sponsors assembled over the past decade was optimized for discrete data collection at fixed time points. An EDC captures a visit. A CTMS tracks the visit schedule. A central lab system logs the sample. That architecture worked when the trial’s most complex biomarker was a six-minute walk test recorded by a coordinator with a stopwatch. It does not work when the biomarker is continuous, sensor-generated, and streaming from a device the patient is wearing at home between visits.
The global digital biomarkers market is projected to grow from USD 4.15 billion in 2024 to USD 32.37 billion by 2034, a compound annual growth rate of 22.74%. That trajectory is not driven by sponsors adding more traditional endpoints. It is driven by wearable sensors, ePRO platforms, and remote monitoring devices generating endpoint-quality data between site visits. The operational consequence for sites is immediate: the data volume coming into a trial is no longer bounded by how many times a coordinator sees a patient. It is bounded only by how many hours are in a day, which means it is effectively unbounded. Legacy biometrics platforms were not priced, staffed, or architected for that throughput.
The FDA’s own draft guidance on the use of artificial intelligence to support regulatory decision-making for drug and biological products signals that the agency is watching how sponsors manage AI-derived data quality and traceability. The guidance addresses how AI tools used in regulatory submissions should be validated and documented — which creates a direct downstream obligation for biometrics vendors and, critically, for the sites whose source data those vendors are processing. If your biometrics CRO cannot demonstrate that its AI pipeline meets the documentation and validation expectations the FDA is signaling, that gap lands in your TMF as an open question during a BIMO inspection.
Sites I work with across our network have started flagging a specific friction point during SIV preparation: the moment when a sponsor’s clinical operations lead presents the eClinical platform stack and the site team realizes the biometrics vendor’s data transfer specifications have not been updated to align with the EDC version the site actually uses. The workaround is always a manual bridge — a coordinator exports, reformats, re-uploads. That process is not ALCOA-C compliant when the timestamp on the re-uploaded file is two hours after the timestamp on the source export. Inspectors notice this. It generates a 483 observation about data integrity controls, which turns into a CAPA, which consumes coordinator hours that were supposed to go toward enrollment.
The Vendor Evaluation Question No One Is Asking Loudly Enough
Paradigm Health closed a $78 million Series B in December 2025, led by ARCH Venture Partners, specifically to expand AI-enabled trial infrastructure into routine care settings. Acrosian launches with an AI-native biometrics model. These are not isolated moves. They represent a structural argument that purpose-built AI infrastructure produces cleaner, faster, more audit-ready biometric data than retrofitted legacy platforms — and that sponsors who have not yet tested that argument are carrying operational risk they have not quantified.
The counterintuitive read here is worth sitting with. Most clinical operations leads assume the risk of switching biometrics vendors mid-program is higher than the risk of staying with a known, credentialed legacy provider. That assumption holds when the trials are similar to what the legacy vendor was built for. It breaks down when the trial’s core endpoints depend on AI-processed sensor data that the legacy vendor is managing through a hybrid workflow it engineered eighteen months ago under a scope change. The operational truth is that a vendor whose architecture requires manual intervention to process your primary endpoint data is not a stable vendor for that endpoint — regardless of how long they have been on your preferred vendor list.
For sponsor-side clinical operations leads, the eClinical stack rationalization question for 2026-2027 planning cycles should include a specific line item: does your current biometrics vendor have a validated AI data pipeline that meets the documentation expectations in the FDA’s current AI guidance, and can they demonstrate it in a vendor audit? That audit preparation takes eight to twelve weeks if the vendor is organized. If it takes longer, or if the vendor cannot produce the validation package, you have your answer before a BIMO inspector finds it for you.
What Changes Monday Morning
For site operations teams, the immediate action is a gap assessment on the eClinical integration points for any trial entering startup in Q3 or Q4 2026. Pull the biometrics vendor’s data transfer specifications and map them against your current EDC version and your site’s source documentation SOP. If the transfer requires any manual reformatting step, document it now as a deviation risk and raise it to the sponsor’s CTM before the SIV — not after the first monitoring visit finds it as a query aging issue. The ICH E6(R3) framework’s emphasis on proportionate risk management applies here directly: a known integration gap that is not escalated before startup is a protocol deviation waiting to be classified.
For sponsors, the vendor consolidation signal from Acrosian’s launch deserves a structured response rather than a wait-and-see posture. The question for your next preferred vendor list review is whether your biometrics infrastructure can handle continuous, AI-processed biomarker data at the volume your 2027 pipeline requires, with the audit trail the FDA’s evolving AI guidance will expect. Sites can absorb a lot — coordinator overtime, manual workarounds, scope expansions — but they cannot absorb a biometrics vendor whose data quality controls fail during a BIMO inspection on your pivotal trial.
The founders of Quartesian spent over two decades building biometrics infrastructure for the trial era that is ending. The fact that they chose to build something new rather than scale something old is the most important operational signal in this story.
References
- FierceBiotech — “Acrosian debuts as AI-focused biometrics CRO”
- PR Newswire — “Quartesian Extends Medidata Expertise to FSP Offering” (founding history and leadership)
- FDA — “Artificial Intelligence in Drug Development” (draft guidance on AI to support regulatory decision-making)
- Towards Healthcare — “Digital Biomarkers Market Sizing” (USD 4.15B to USD 32.37B, 2024-2034, CAGR 22.74%)
- PR Newswire — “Paradigm Health Raises $78 Million Series B” (December 2025, led by ARCH Venture Partners)
